Stock Events

Stock Events

Unicycive Therapeutics 

$5.16
83
-$0.14-2.64% Friday 20:00
+$0.04+0.78%Friday 23:35After hours

Statistics

Day High
5.16
Day Low
5.15
52W High
8.74
52W Low
3.71
Volume
10,007
Avg. Volume
-
Mkt Cap
143.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.68
-0.47
-0.26
-0.05
Expected EPS
-0.348
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-26.56MNet Income

Analyst Ratings

25.00Average Price Target
The highest estimate is 50.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UNCY. It's not an investment recommendation.
NVIDIA
16
NVDA
Amazon
14
AMZN
Apple
13
AAPL
Tesla
12
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, potentially overlapping with Unicycive's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences competes in the development of innovative therapeutics, including for liver diseases, which may intersect with Unicycive's focus areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in similar therapeutic areas, including renal disease and other serious health conditions, making it a direct competitor.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on novel therapies for serious illnesses, including kidney diseases, which could compete with Unicycive's product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare diseases with its advanced therapies, potentially competing in niche markets targeted by Unicycive.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing treatments for serious medical conditions, which may include areas of interest to Unicycive.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a leading company in diabetes care but also explores treatments for other chronic conditions, potentially competing with Unicycive.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes treatments for renal diseases and other areas that could overlap with Unicycive's interests.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse portfolio in various therapeutic areas, including those that could compete with Unicycive's focus on kidney diseases.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that develops medicines for a wide range of diseases, some of which may compete with Unicycive's therapies.

About

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Show more...
CEO
Shalabh K. Gupta
Employees
22
Country
United States
ISIN
US90466Y2028

Listings

BOATS
BOATS
UNCY.BOATS
XNAS
US
UNCY

0 Comments

Share your thoughts

FAQ

What is Unicycive Therapeutics stock price today?▼
The current price of UNCY is $5.16 USD — it has decreased by -2.64% in the past 24 hours. Watch Unicycive Therapeutics stock price performance more closely on the chart.
What is Unicycive Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Unicycive Therapeutics stocks are traded under the ticker UNCY.
Is Unicycive Therapeutics stock price growing?▼
UNCY stock has fallen by -1.99% compared to the previous week, the month change is a -1.34% fall, over the last year Unicycive Therapeutics has showed a +18.35% increase.
What is Unicycive Therapeutics market cap?▼
Today Unicycive Therapeutics has the market capitalization of 143.73M
When is the next Unicycive Therapeutics earnings date?▼
Unicycive Therapeutics is going to release the next earnings report on November 18, 2026.
What were Unicycive Therapeutics earnings last quarter?▼
UNCY earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.47 USD resulting in a +87.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Unicycive Therapeutics revenue for the last year?▼
Unicycive Therapeutics revenue for the last year amounts to 0 USD.
What is Unicycive Therapeutics net income for the last year?▼
UNCY net income for the last year is -26.56M USD.
How many employees does Unicycive Therapeutics have?▼
As of September 05, 2026, the company has 22 employees.
In which sector is Unicycive Therapeutics located?▼
Unicycive Therapeutics operates in the Health & Wellness sector.
When did Unicycive Therapeutics complete a stock split?▼
The last stock split for Unicycive Therapeutics was on June 20, 2025 with a ratio of 1:10.
Where is Unicycive Therapeutics headquartered?▼
Unicycive Therapeutics is headquartered in MOUNTAIN VIEW, United States.